Old Web
English
Sign In
Acemap
>
authorDetail
>
Robert J. Gazak
Robert J. Gazak
Eli Lilly and Company
Neutropenia
Dosing
Toxicity
Pharmacokinetics
Medicine
2
Papers
79
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
2004
Clinical Cancer Research
Paula M. Fracasso
Lori J. Goldstein
Dinesh P. de Alwis
Janet S. Rader
Matthew A. Arquette
Sherry A. Goodner
Lisa P. Wright
Carole L. Fears
Robert J. Gazak
Valérie André
Michael Burgess
Christopher A. Slapak
Jan H. M. Schellens
Show All
Source
Cite
Save
Citations (65)
A Phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
2003
Clinical Cancer Research
Bahram Forouzesh
Chris H. Takimoto
Andrew Goetz
Sami G. Diab
Lisa A. Hammond
Leslie Smetzer
Garry Schwartz
Robert J. Gazak
John T. Callaghan
Daniel D. Von Hoff
Eric K. Rowinsky
Show All
Source
Cite
Save
Citations (14)
1